Sign In
Buy ALNY
$301.03
+7.51 (+2.56%)
At Close: Jun 30, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
05:12pm, Thursday, 25'th Jun 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
09:00am, Thursday, 25'th Jun 2026
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasd
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
09:31am, Monday, 22'nd Jun 2026
Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term
10:51am, Tuesday, 16'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
10:21am, Friday, 12'th Jun 2026
Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
09:00am, Friday, 12'th Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” w
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
07:47am, Wednesday, 10'th Jun 2026
ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
08:22pm, Tuesday, 09'th Jun 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts
01:04pm, Tuesday, 09'th Jun 2026
Alnylam Pharmaceuticals NASDAQ: ALNY executives outlined the company's 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst S
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500
05:06pm, Monday, 08'th Jun 2026
The index added two companies on Friday, but more are likely to be added in the near future.
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
12:31pm, Thursday, 04'th Jun 2026
ALNY teams up with Inceptive in a deal worth up to $2B, using AI models and proprietary RNAi data to speed drug discovery and improve candidate selection.
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion
11:52am, Thursday, 04'th Jun 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock is up on Thursday after the company announced a strategic collaboration with Inceptive Nucleics, valued at up to $2 billion.
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
06:05pm, Wednesday, 03'rd Jun 2026
Alnylam Pharmaceuticals said on Wednesday it has teamed up with artificial-intelligence biotech Inceptive in a deal worth up to $2 billion to use AI to speed up discovery of RNA-based medicines.
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
04:45pm, Wednesday, 03'rd Jun 2026
CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models
